Here are the Form 4 insider transactions from United Therapeutics Corp (UTHR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UTHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTHR filings page.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on April 10, 2026. The options were originally granted with an expiration date of March 15, 2027.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices ranging from about $567 to $573 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 shares directly and also reported indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a pre-planned transaction. On April 9, 2026, he exercised options for 10,000 shares of Common Stock at an exercise price of $135.42 per share.
On the same date, he sold a total of 10,000 shares of Common Stock in multiple open-market trades at prices reported between about $574.18 and $582.30. These transactions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating they were pre-scheduled.
Following the transactions, Edgemond directly owned 18,876 shares of UNITED THERAPEUTICS Common Stock, maintaining a meaningful equity stake while monetizing the shares received from the option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in open-market transactions. The sales occurred at prices around the mid-$570s to low-$580s per share, with reported weighted average prices including $575.04 and $580.84.
The exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following these transactions, Rothblatt directly holds 40,513 shares of common stock and 74,000 stock options, with additional indirect holdings through a spouse and multiple family trusts.
United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 8, 2026, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in multiple open-market trades at prices generally ranging from about $565 to $586 per share, leaving 40,513 shares held directly. Additional common shares are held indirectly through her spouse and various family trusts as described in the filing. All option exercises and related sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. She exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market trades, with reported prices including $556.89, $562.35 and $569.62 per share. Following these transactions, she held 40,513 shares of common stock directly, plus additional indirect holdings through her spouse and family trusts, including positions of 324,518 and 258,117 shares as of the filing.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share. On the same date, he sold 10,000 shares of common stock in multiple open-market trades at prices generally in the mid-$550s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of common stock and 112,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold the resulting shares in a planned transaction. On 2026-04-06, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold 9,500 shares in multiple open-market trades at prices ranging from $552.37 to $566.04.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired 9,500 shares on April 2, 2026. She then sold 9,500 shares of common stock the same day in a series of open‑market transactions at prices in the mid‑$500s per share, leaving her with 40,513 shares held directly. The filing also shows substantial additional indirect holdings through family trusts and a spouse. The exercise and sale were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of up to 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions. The sales occurred at weighted average prices within ranges described in the filing, including from $551.68 to $571.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, Edgemond directly holds 18,876 shares of United Therapeutics Common Stock.
UNITED THERAPEUTICS Corp EVP & General Counsel Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share and received 8,300 shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices generally around the mid-$560s per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options for common stock at $146.03 per share and sold the resulting 9,500 shares in multiple open-market trades on April 1, 2026. The reported sale prices ranged from about the high $570s to high $590s per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly, plus indirect interests in shares held by her spouse and various family trusts. The plan permits exercise of up to 1,734,410 stock options that expire on March 17, 2027, and continues until those are exercised or December 31, 2026, whichever comes first.
United Therapeutics Chairperson and CEO Martine Rothblatt reported several insider transactions. On March 31, 2026, she exercised stock options to acquire 9,500 shares of Common Stock at an exercise price of $146.03 per share and sold the same 9,500 shares in multiple open-market trades at prices ranging from about $574.55 to $594.18 under a pre-arranged Rule 10b5-1 trading plan.
Following these trades, she directly holds 40,513 shares of Common Stock and stock options for 150,808 shares at an exercise price of $135.42 expiring in March 2027. In addition, family trusts associated with her made bona fide gifts totaling 1,698,384 stock options with exercise prices of $135.42 and $117.76, with no funds exchanged and no sale of shares in connection with these gifts.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged trading plan. On March 30, 2026, she exercised options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share, converting a derivative position into common stock.
That same day she sold 9,500 common shares in multiple open-market transactions at prices generally around $581–$603 per share, as part of a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 common shares directly, in addition to indirect holdings reported as held by her spouse and various family trusts.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share, then sold 10,000 shares in a series of open-market trades at prices generally around $582–$607 per share.
After these transactions, he directly owns 18,876 shares of common stock and holds 132,500 stock options. The exercise and subsequent sales were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the trades were scheduled in advance.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options and sold shares in a pre-planned transaction. He exercised options for 1,300 shares of Common Stock at an exercise price of $119.76 per share and then sold 1,300 shares at $604.64 per share on the same date. These moves were executed under a Rule 10b5-1 trading plan entered into on September 30, 2025, indicating the trades were scheduled in advance. Following the transactions, he directly held 4,190 shares of Common Stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the underlying shares. She then sold 9,500 common shares in multiple open-market transactions on March 27, 2026 at prices generally above $522 per share, with trades executed in ranges described in the filing.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, Rothblatt holds 40,513 common shares directly and also reports additional indirect holdings through her spouse and various family trusts.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and, on the same date, sold 9,500 shares in a series of open-market transactions at prices around $531–$540 per share.
The filing shows this exercise-and-sell activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of up to 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Following these trades, Rothblatt holds 40,513 shares of common stock directly, plus additional indirect holdings through a spouse and several family trusts.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and acquired the related common shares.
On the same March 26, 2026, he sold a total of 10,000 common shares in multiple open‑market transactions at weighted average prices around $532–$540, pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 common shares.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in open-market transactions on March 25, 2026. The filing shows this exercise and sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these trades, she holds 40,513 shares directly, alongside additional indirect holdings, including 324,518 shares held by certain family trusts and 166 shares held by her spouse.
United Therapeutics director Tommy G. Thompson reported an option exercise and related share sales. He exercised stock options for 2,000 shares of common stock at $101.80 per share and received 2,000 shares on March 26, 2026. He then sold a total of 2,000 common shares in three open-market transactions at weighted average prices of $537.6192, $539.2451, and $540.1750 per share. After these transactions, he holds 8,480 common shares directly, plus indirect holdings of 8,200 shares held by a trust and 5,800 shares held by a family LLC. A footnote also notes 880 additional shares are scheduled to be issued on or about July 8, 2026 from previously vested deferred RSUs.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share and acquired 9,500 shares of common stock on March 24, 2026. She then sold 9,500 common shares in multiple open‑market trades at prices between approximately $516.84 and $536.02, leaving 40,513 shares held directly.
The filing also lists additional indirect holdings, including shares held by her spouse and in various family trusts. A footnote states these transactions were made under a pre‑arranged 10b5‑1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at reported prices such as $518.2830, $529.0430 and $536.2750 per share. Following these transactions, he directly holds 18,876 shares of common stock. The exercise and subsequent sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share and sold the resulting 9,500 shares in multiple open‑market trades on March 23, 2026.
The sales occurred at weighted average prices ranging from about $517.81 to $536.55, pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. After these transactions, she holds 40,513 shares directly, plus indirect holdings including 166 shares held by her spouse and family trust positions of 324,518, 258,117, 45,596 and 10,962 shares.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of 200 shares of common stock at $530 per share. The transaction occurred on March 23, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan entered into on November 4, 2025. After this sale, she directly holds 4,245 shares of UNITED THERAPEUTICS common stock.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share. She then sold 9,500 shares of common stock in a series of open-market transactions at prices above $520 per share, creating an exercise-and-sell pattern.
The filing shows she holds 40,513 common shares directly after these trades, plus indirect holdings including 166 shares held by her spouse and trust holdings of 324,518, 258,117, 45,596 and 10,962 shares. The exercise and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until up to 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold the same 9,500 shares in multiple open-market transactions.
The sales occurred on March 19, 2026 at weighted-average prices ranging from about $524.62 to $532.90, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly and also reports indirect holdings through her spouse and family trusts, including 324,518 shares held by a family trust.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned options exercise and sale. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices generally between the $522 and $540 range, under a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.
United Therapeutics executive Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, converting them into common shares.
The same day, he sold a total of 8,300 common shares in multiple open-market trades pursuant to a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of United Therapeutics common stock.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share, then sold 9,500 shares in multiple open-market trades around $531–$541 on March 17, 2026.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.
United Therapeutics Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, converting options into shares.
On the same date, she sold 9,500 common shares in a series of open-market trades at prices ranging from $528.51 to $537.37 per share, leaving 40,513 shares held directly. The filing also lists additional indirect holdings through her spouse and several family trusts. All transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported routine equity compensation activity involving restricted stock units and common shares. On March 15, 2026, a trust associated with him exercised restricted stock units that each convert into one share of common stock, resulting in 33,382 shares of common stock held indirectly by the trust.
Of these shares, 14,706 shares of common stock were withheld by United Therapeutics to satisfy tax obligations upon vesting, a non-market disposition that does not represent an open-market sale. Following these transactions, the filing shows 19,046 shares held indirectly by the trust and 2,710 shares held directly, which includes 62 shares acquired earlier under the company’s employee stock purchase plan.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised restricted stock units into 19,478 shares of common stock on March 15, 2026. These awards converted one-for-one into common shares following vesting, reflecting performance-based and time-based equity compensation.
To cover tax obligations at vesting, 8,786 shares were withheld by United Therapeutics at a price of $536.12 per share. These F-code transactions are tax-withholding dispositions, not open-market sales. After all transactions, Edgemond directly holds 18,876 shares of common stock, including 42 shares acquired under the employee stock purchase plan.
United Therapeutics EVP & General Counsel Paul A. Mahon reported the vesting and conversion of restricted stock units into common shares. On March 15, 2026, 16,691 restricted stock units converted on a one-for-one basis into 16,691 shares of common stock, reflecting time- and performance-based awards granted in March 2023.
To cover tax obligations upon vesting, 8,363 of these shares were withheld by United Therapeutics at a reference price of $536.12 per share, rather than sold in the open market. After these transactions, Mahon directly owns 45,172 shares of United Therapeutics common stock.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported vesting and settlement of restricted stock units rather than open-market trades. On March 15, 2026, she exercised and converted a total of 69,579 restricted stock units into the same number of common shares on a one-for-one basis.
To cover tax obligations associated with these vestings, 29,196 common shares were withheld by United Therapeutics at $536.12 per share, a non-market tax-withholding disposition. After these transactions, Rothblatt directly held 40,513 shares of common stock, and the filing also shows additional indirect holdings through her spouse and various family trusts.
United Therapeutics director Jan Malcolm reported an open-market sale of company stock. On March 17, 2026, Malcolm sold 45 shares of Common Stock at an average price of $533.51 per share, and now directly holds 125 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Malcolm entered into on September 11, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On March 16, 2026, she sold 200 shares of Common Stock at an average price of $535.44 per share in a sale classified as an open-market transaction.
After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and on the same date sold 9,500 shares in open-market trades at weighted average prices between $535.43 and $542.04. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the transactions, she holds 7,150 shares directly and additional indirect holdings through her spouse and family trusts totaling several hundred thousand shares.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 12, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day and on March 16, 2026, she completed open-market sales totaling 9,500 common shares at weighted average prices generally between $531.94 and $544.80. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these trades, Rothblatt holds 8,414 shares of common stock directly. She also has indirect interests, including 166 shares held by her spouse and shares held in various family trusts, such as 324,518 shares in one trust where family members are beneficiaries.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the same number of shares. On the same March 11, 2026, she sold 9,500 common shares in multiple open‑market transactions at prices ranging from $531.90 to $544.94, leaving 130 shares held directly.
The options exercised were originally granted on March 15, 2020 and were scheduled to expire on March 15, 2027. The filing also shows additional indirect holdings, including shares held by a spouse and in several family trusts, such as 324,518 and 258,117 shares reported as held by trusts. All option exercises and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices generally between about $530 and $548 per share. These transactions on March 10, 2026 were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to execute trades automatically over time. Following the sales, she holds 130 shares directly and also has substantial indirect holdings through family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 9, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in a series of open-market trades, including 200 shares at $500.05 per share and 80 shares at $529.83 per share. After these trades, she held 130 shares directly, and also reported additional indirect holdings through her spouse and several family trusts.
The footnotes state that this option exercise and sale of resulting shares were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on March 6, 2026. She then sold 9,500 shares in multiple open-market transactions at prices reported between $471.96 and $484.27 per share.
The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the sales, she holds 130 shares directly and additional indirect holdings through her spouse and family trusts.
UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction. On March 6, 2026, she completed an open-market sale of 200 shares of common stock at a price of $510 per share, leaving her with 4,645 shares held directly.
According to a footnote, this sale was made under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025. Such plans are designed to allow insiders to systematically sell shares over time according to predetermined instructions.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares on March 5, 2026, converting derivative securities into common stock at a reported exercise price of $146.03 per share.
On the same date, she sold a total of 9,500 common shares in a series of open-market transactions, with reported weighted-average prices ranging from $479.8871 to $487.9813, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 130 common shares, in addition to indirect holdings reported as 166 shares by spouse and 324,518, 258,117, 45,596 and 10,962 shares held by various family trusts.
UNITED THERAPEUTICS Corp executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options and selling resulting shares. On March 5, 2026, he exercised 8,300 stock options at a reported price of $0.0000 per option, receiving 8,300 shares of common stock at a reported price of $146.0300 per share.
The filing shows multiple open-market sales totaling 8,300 shares of common stock on the same date at reported weighted average prices between about $479.4271 and $487.6520. A footnote states these option exercises and related sales were made under a pre-arranged 10b5-1 trading plan entered into on August 11, 2025. After these transactions, Mahon directly held 36,844 shares of common stock and 33,500 stock options as of March 5, 2026, including 63 shares acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported an insider transaction involving stock options and common shares. On March 4, 2026, she exercised 9,500 stock options (labeled as Stock Options) at a reported exercise price of $0.0000 per share, leaving her with 211,500 stock options held directly following the exercise.
The same day, she executed a series of open-market sales totaling 19,000 shares of Common Stock, with reported per‑share prices including $486.4229 and up to $497.0500. After these sales, she held 130 shares of Common Stock directly. Additional indirect Common Stock holdings are reported as 166 shares held by spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. A footnote states that the option exercise and related share sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of 101.8000. On the same date, he then sold 4,910 shares of common stock at a reported price per share of 489.0200. After these transactions, his directly owned common stock holdings were 12,670 shares.
UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on March 4, 2026. He exercised a stock option for 2,000 options, labeled as an exercise or conversion of a derivative security, resulting in 2,000 options held afterward.
On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of $101.8000 per share, bringing his direct common stock holdings to 10,480 shares. He then executed an open-market sale of 2,000 common shares at a weighted average price of $489.4197 per share, leaving 8,480 directly held shares.
A footnote states that his direct holdings include 880 additional common shares to be issued on or about July 8, 2026 from previously vested RSUs for which receipt was deferred. Indirectly, 8,200 common shares are held by a trust and 5,800 common shares are held through a Family LLC associated with him.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options for 20 shares on March 4, 2026, converting them into common stock at a price of $119.76 per share. He then sold 20 common shares in an open-market transaction at a weighted average price of $490.1685 per share.
The option exercise and subsequent sale were carried out under a pre-arranged Rule 10b5-1 trading plan that Causey entered into on September 30, 2025. The sale occurred in multiple trades, with individual prices ranging from $490.12 to $490.21, and left him with 4,190 common shares held directly.
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.